SAN DIEGO -- Adjuvant chemoradiation may benefit some women with advanced endometrial cancer, researchers said here.
SAN DIEGO, March 7 -- Adjuvant chemoradiation may benefit some women with advanced endometrial cancer, researchers said here.
In a retrospective study, the adjuvant chemoradiation significantly improved overall survival in all patients, compared with chemotherapy (P=0.05) or radiation alone (P=0.014), according to Angeles Alvarez Secord, M.D., of Duke Medical Center in Durham, N.C.
The combination did not significantly improve progression-free survival over chemotherapy alone, but gave a slight improvement over radiation alone (P=0.043), Dr. Secord told a plenary session of the Society of Gynecologic Oncologists meeting.
However, when the analysis was restricted to patients whose tumors had been optimally debulked, Dr. Secord said, both overall and progression-free survival were markedly improved.
The study suggested the possibility of improved care for some patients, Dr. Secord said, but she stopped short of saying that combination therapy should be the standard of care.
"I really think you need to individualize therapy based on pathologic factors as well as co-morbidities," she said, noting that the combined therapy would increase toxicity, which might not be appropriate in some patients.
Dr. Secord and colleagues analyzed data on patients at Duke and the University of North Carolina at Chapel Hill over a 36-year period, from 1970 to 2006.
To be eligible for the analysis, she said, patients had to have had stage III or IV endometrial cancer, a comprehensive surgical staging, and surgical debulking before going on to adjuvant treatment.
The researchers found 356 patients who fit their criteria, of whom 102 had chemotherapy alone, 171 had radiation alone, and 83 had both. There were significantly more (P